Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma.
Authors: Dong SM,  Pai SI,  Rha SH,  Hildesheim A,  Kurman RJ,  Schwartz PE,  Mortel R,  McGowan L,  Greenberg MD,  Barnes WA,  Sidransky D
Journal: Cancer Epidemiol Biomarkers Prev
Date: 2002 Jan
Branches: MEB
PubMed ID: 11815394
PMC ID: not available
Abstract: Human papillomaviruses (HPVs) play a central role in the development of cervical carcinoma. Plasma DNA from 232 patients taken at diagnosis or after treatment for invasive cervical cancer (n = 175) or carcinoma in situ (n = 57) and 60 normal controls were examined for HPV-16 or HPV-18 E7 DNA by conventional and real-time quantitative PCR assays. We found HPV-16 or HPV-18 E7 DNA in 6.9% (11 of 175) of invasive cervical cancer cases (18.1% of cases positive for HPV-16 or HPV-18 at the genital tract), 1.8% (1 of 57) of carcinoma in situ, and 1.7% (1 of 60) of normal controls by conventional PCR. Quantitative PCR identified the highest concentrations of HPV DNA (copy number of HPV/ml of plasma) in patients with invasive cervical cancer (mean, 11,163; median, 183.5), followed by a level of 8 in the single carcinoma in situ case and 0 copies in the normal control initially positive by conventional PCR. HPV DNA can be detected in the plasma of some patients with HPV-positive cervical tumors. It remains to be demonstrated whether quantitative PCR analysis of HPV DNA in plasma may have utility in patients at high risk of recurrent disease.